Literature DB >> 19214667

Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K(2).

Teruhisa Yamamoto1, Hideji Nakamura, Weidong Liu, Ke Cao, Shohei Yoshikawa, Hirayuki Enomoto, Yoshinori Iwata, Noritoshi Koh, Masaki Saito, Hiroyasu Imanishi, Soji Shimomura, Hiroko Iijima, Toshikazu Hada, Shuhei Nishiguchi.   

Abstract

BACKGROUND: Vitamin K(2) has been reported to suppress the growth of human hepatocellular carcinoma (HCC) in vitro and hepatocarcinogenesis in hepatitis C virus (HCV)-related cirrhosis in vivo. Hepatoma-derived growth factor (HDGF) is a unique nuclear targeting growth factor that is highly expressed in HCC cells and is a possible prognostic factor for patients with HCC. We investigated the regulation of HDGF expression by vitamin K(2).
METHODS: Three HCC-derived cell lines, HepG2, HuH-7, and SK-Hep-1, were used. Cell number was determined with the MTT assay. The expression levels of HDGF mRNA and protein were measured by the real-time reverse transcriptase-polymerase chain reaction (PCR) method and ELISA and Western blot analysis, respectively. The HDGF promoter activity was measured by a dual luciferase-reporter assay.
RESULTS: Vitamin K(2) suppressed the growth of the three HCC cell lines in a dose-dependent manner. Vitamin K(2) significantly suppressed the expression of the HDGF protein and mRNA in three cell lines. By a luciferase assay, vitamin K(2) significantly suppressed the promoter activity of the HDGF protein. Based on some luciferase-reporter plasmids containing truncated promoter regions, the possible responsive site of vitamin K(2) seems to reside in the region -1 to -150 bp of the HDGF gene.
CONCLUSIONS: These findings suggested that regulation of the HDGF gene expression is one of the crucial mechanisms of vitamin K(2)-induced cell growth suppression for HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19214667     DOI: 10.1007/s00535-008-2304-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  32 in total

1.  Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma.

Authors:  Shinji Yamamoto; Yasuhiko Tomita; Yoshihiko Hoshida; Shuji Takiguchi; Yoshiyuki Fujiwara; Takushi Yasuda; Yuichiro Doki; Kenya Yoshida; Katsuyuki Aozasa; Hideji Nakamura; Morito Monden
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

2.  Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma.

Authors:  Kenya Yoshida; Yasuhiko Tomita; Yorihide Okuda; Shinji Yamamoto; Hirayuki Enomoto; Hirokazu Uyama; Hiroaki Ito; Yoshihiko Hoshida; Katsuyuki Aozasa; Hiroaki Nagano; Masato Sakon; Ichiro Kawase; Morito Monden; Hideji Nakamura
Journal:  Ann Surg Oncol       Date:  2006-01-17       Impact factor: 5.344

3.  Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals.

Authors:  Yoshihiko Kishima; Hiroyasu Yamamoto; Yoshitaka Izumoto; Kenya Yoshida; Hirayuki Enomoto; Mitsunari Yamamoto; Toshifumi Kuroda; Hiroaki Ito; Kazuyuki Yoshizaki; Hideji Nakamura
Journal:  J Biol Chem       Date:  2001-12-18       Impact factor: 5.157

4.  Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.

Authors:  Iwata Ozaki; Hao Zhang; Toshihiko Mizuta; Yasushi Ide; Yuichiro Eguchi; Tsutomu Yasutake; Toshiyuki Sakamaki; Richard G Pestell; Kyosuke Yamamoto
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

5.  Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development.

Authors:  A D Everett; D R Lobe; M E Matsumura; H Nakamura; C A McNamara
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

6.  Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells.

Authors:  A D Everett; T Stoops; C A McNamara
Journal:  J Biol Chem       Date:  2001-07-31       Impact factor: 5.157

7.  Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.

Authors:  Hening Ren; Ximing Tang; J Jack Lee; Lei Feng; Allen D Everett; Waun Ki Hong; Fadlo R Khuri; Li Mao
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

8.  Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver.

Authors:  Daiki Habu; Susumu Shiomi; Akihiro Tamori; Tadashi Takeda; Takashi Tanaka; Shoji Kubo; Shuhei Nishiguchi
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

9.  Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation.

Authors:  Motoyuki Otsuka; Naoya Kato; Run-Xuan Shao; Yujin Hoshida; Hideaki Ijichi; Yukihiro Koike; Hiroyoshi Taniguchi; Masaru Moriyama; Yasushi Shiratori; Takao Kawabe; Masao Omata
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

10.  Vitamin K2 inhibits the proliferation of HepG2 cells by up-regulating the transcription of p21 gene.

Authors:  Weidong Liu; Hideji Nakamura; Teruhisa Yamamoto; Naoto Ikeda; Masaki Saito; Masao Ohno; Naoki Hara; Hiroyasu Imanishi; Soji Shimomura; Tetsuo Yamamoto; Toshiyuki Sakai; Shuhei Nishiguchi; Toshikazu Hada
Journal:  Hepatol Res       Date:  2007-05       Impact factor: 4.288

View more
  12 in total

1.  A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.

Authors:  Ye Song; Zheng Hu; Hao Long; Yuping Peng; Xi'an Zhang; Tianshi Que; Shihao Zheng; Zhiyong Li; Gang Wang; Liu Yi; Zhen Liu; Weiyi Fang; Songtao Qi
Journal:  J Neurooncol       Date:  2014-07-02       Impact factor: 4.130

2.  Induction of apoptosis in hepatocellular carcinoma Smmc-7721 cells by vitamin K(2) is associated with p53 and independent of the intrinsic apoptotic pathway.

Authors:  Lu Li; Zhiling Qi; Jin Qian; Fuyong Bi; Jun Lv; Lei Xu; Ling Zhang; Hongyu Chen; Renbing Jia
Journal:  Mol Cell Biochem       Date:  2010-05-07       Impact factor: 3.396

3.  Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas.

Authors:  Shu-Shong Hsu; Chih-Hao Chen; Guei-Sheung Liu; Ming-Hong Tai; Jyh-Seng Wang; Jain-Ching Wu; Mei-Lang Kung; Elsa C Chan; Li-Feng Liu
Journal:  J Neurooncol       Date:  2011-10-26       Impact factor: 4.130

4.  Partial blockage of hepatocyte maturation in hepatoma-derived growth factor transgenic mice.

Authors:  Hirayuki Enomoto; Hideji Nakamura; Naoko Komatsu-Kanatani; Yu Liu; Kenya Yoshida; Yorihide Okuda; Teruhisa Yamamoto; Weidong Liu; Shuhei Nishiguchi
Journal:  World J Hepatol       Date:  2009-10-31

5.  Hepatoma-derived growth factor: A survival-related protein in prostate oncogenesis and a potential target for vitamin K2.

Authors:  Aditya Shetty; Subramanyam Dasari; Souresh Banerjee; Taher Gheewala; Guoxing Zheng; Aoshuang Chen; Andre Kajdacsy-Balla; Maarten C Bosland; Gnanasekar Munirathinam
Journal:  Urol Oncol       Date:  2016-09-28       Impact factor: 3.498

Review 6.  Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications.

Authors:  Ashley H Davis-Yadley; Mokenge P Malafa
Journal:  Adv Nutr       Date:  2015-11-13       Impact factor: 8.701

Review 7.  Hepatoma-Derived Growth Factor: Its Possible Involvement in the Progression of Hepatocellular Carcinoma.

Authors:  Hirayuki Enomoto; Hideji Nakamura; Weidong Liu; Shuhei Nishiguchi
Journal:  Int J Mol Sci       Date:  2015-06-19       Impact factor: 5.923

Review 8.  Vitamin K and its analogs: Potential avenues for prostate cancer management.

Authors:  Subramanyam Dasari; Syed M Ali; Guoxing Zheng; Aoshuang Chen; Venkata Satish Dontaraju; Maarten C Bosland; Andre Kajdacsy-Balla; Gnanasekar Munirathinam
Journal:  Oncotarget       Date:  2017-05-19

9.  Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.

Authors:  Jian-Hong Zhong; Xin-Shao Mo; Bang-De Xiang; Wei-Ping Yuan; Jin-Fang Jiang; Gui-Sheng Xie; Le-Qun Li
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

10.  Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells.

Authors:  Abhilash Samykutty; Aditya V Shetty; Gajalakshmi Dakshinamoorthy; Ramaswamy Kalyanasundaram; Gouxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla; Munirathinam Gnanasekar
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.